The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

Completed

• Conditions: Scleroderma

• Registration Number: NCT02887495
• Lead Sponsor: George Washington University

Brief Summary

The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-07
• Study First Submitted: 2015-02-03
• Study First Submitted QC: 2016-08-29
• Study First Posted: 2016-09-02
• Primary Completion: 2022-02-02
• Study Completion: 2022-02-02
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-25
• Last Update Posted: 2022-07-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 600

Inclusion Criteria

• Age >18 years
• Able to give informed consent.
• Diagnosed with scleroderma or with positive autoantibodies

Exclusion Criteria

• < 18 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Modified Rodnan Skin Score	10 years

Secondary Outcome Measures

Name	Time	Method
Medsger Severity Score	10 years

Trial Locations

Locations (1)

Victoria K Shanmugam; 🇺🇸 Washington, District of Columbia, United States